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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not oral
rivaroxaban is safe and effective in the treatment of patients with symptomatic DVT.
STUDY DESIGN: Review of three English language primary randomized controlled trial studies
published from 2007-2011.
DATA SOURCES: Three randomized controlled trials studying the effectiveness and safety of
rivaroxaban in the treatment of patients with symptomatic DVT in comparison to enoxaparin and
placebo.
OUTCOMES MEASURED: Outcomes measured were episodes of recurrent DVT and bleeding.
Patients were monitored for the proposed treatment period and seen at fixed intervals that were
matching for the rivaroxaban and comparison groups. At this time a checklist was used to gather
information on symptoms and signs of recurrent venous thromboembolism, bleeding, and
adverse events.
RESULTS: The articles showed rivaroxaban is safe and effective in the treatment of patients
with deep venous thrombosis. The primary efficacy outcome in all was episodes of recurrent
DVT. The principle safety outcome in all studies was clinically relevant major and non-major
bleeding.
CONCLUSIONS: This review supports the use of rivaroxaban in the treatment of patients with
symptomatic deep venous thrombosis. More information is needed for the use of the drug in
special populations such as cancer patients.
KEY WORDS: Rivaroxaban, Treatment, DVT

INTRODUCTION
Deep venous thrombosis (DVT) is a blood clot that most commonly forms in the deep
veins of the arms or legs and may lead to emboli. A clot forms when something slows or causes
an alteration in blood flow such as hospitalization. This paper evaluates three randomized,
controlled trials (double blind, parallel group phase II, open label) in the safety and effectiveness
of rivaroxaban in the treatment of patients with symptomatic DVT. The precise number of
people affected by DVT is unknown, but estimates range from 300,000 to 600,000 (1 to 2 per
1,000, and in those over 80 years of age, 1 in 100) each year in the US.4 33% of people with
DVT will have a recurrence within 10 years.4 The total annual healthcare cost for a Venous
Thromboembolism (VTE) ranged from $7594 to $16,644, depending on the type of event and
whether it was a primary or secondary diagnosis.5 The recurrent DVT event was associated with
21% greater cost compared with the initial DVT event.5 DVT was diagnosed in an estimated
annual average of 348,558 hospitalizations.6
Various factors can lead to DVT such as age, obesity, smoking, heart failure, oral
contraception, venous stasis due to immobilization, cancer, stroke, pregnancy, polycythemia
vera, factor deficiencies, etc. Among people who have had a DVT, 50% will have long-term
symptoms such as swelling, pain, discoloration, and scaling in the affected limb.4 Numerous
methods are used to treat the condition including unfractionated or low molecular weight
heparin, vitamin K antagonists, selective factor Xa inhibitors, direct thrombin inhibitor, inferior
vena cava filters, and fibrinolytic therapy. Current treatments of DVT have limitations due to the
required laboratory monitoring for dose initiation and adjustment, narrow therapeutic window,
and are subject to food and drug interactions.2 Rivaroxaban is being proposed as an alternative in

treatment because it does not need laboratory monitoring, has a wide therapeutic window, is safe
in long term use, and has oral route of administration.3
OBJECTIVE
The objective of this selective EBM review is to determine whether or not oral
rivaroxaban is safe and effective in the treatment of patients with symptomatic DVT.
METHODS
Articles designated for this selective evidence based medicine (EBM) review have met
precise requirements to explore the objective. The articles consisted of three randomized control
trials. The articles were selected using the key words: rivaroxaban, treatment, and DVT. The
author of this selective EBM review conducted the research in PubMed, Cochrane, and OVID.
All articles were published in the English language in peer-reviewed journals. Articles were
chosen if they targeted patients with DVT, included patient oriented outcomes, and population
age greater than 18. Articles were excluded if they were systematic reviews, non- patient
oriented outcomes, and population age less than 18. Statistics were reported using p-values, 95%
confidence intervals (CI), relative risk reduction (RRR), absolute risk reduction (ARR), relative
risk increase (RRI), absolute risk increase (ARI), number needed to treat (NNT), and number
needed to harm (NNH).
In the Einstein’s study which was an open label, randomized, event driven, noninferiority study patients were assigned to receive oral rivaroxaban 15mg twice daily for the first
three weeks, followed by 20mg once daily for the anticipated 3, 6, or 12 months of treatment.1 In
Agnelli’s group phase II trial study the oral rivaroxaban group received doubled blinded doses of
10, 20, or 30mg twice daily or 40mg once daily, with food for 12 weeks.2 In both studies patients

in the standard anticoagulant group received subcutaneous enoxaparin 1mg/kg twice daily
followed by vitamin K antagonist such as warfarin. In Roumaldi’s double blind, placebo
controlled superiority study, patients were assigned to receive rivaroxaban 20mg or placebo for
6-12 months.3 Outcomes measured include incidence of recurrent DVT and bleeding. The
demographics of the studies included are demonstrated in Table 1.
OUTCOMES MEASURED
The primary efficacy outcomes of the studies was the incidence of symptomatic recurrent
VTE, defined as a composite of DVT and pulmonary embolism.3 The safety outcome measured
in all the studies is bleeding. Bleeding was considered major if it was fatal, affected a critical
organ, led to treatment cessation, or transfusion of two or more units of packed red blood cells or
whole blood.2 Patients were monitored for the proposed treatment period and seen at fixed
intervals that were matching for the rivaroxaban and comparison groups. At this time a checklist
was used to gather information on symptoms and signs of recurrent venous thromboembolism,
bleeding, and adverse events.
RESULTS
Three randomized control trials evaluated in this review include a parallel group phase II
trial, an open label event driven, noninferiority study and a double blind, event driven superiority
study. Two of the studies compared rivaroxaban to enoxaparin plus vitamin K antagonist while
one compared rivaroxaban to placebo. Patients included in the studies were all of legal age for
consent and had symptomatic DVT. The primary efficacy outcome in all studies was episodes of
recurrent DVT. The principle safety outcome in all studies was clinically relevant major and
non-major bleeding. The principle safety outcome was measured via events such as treatment

Table 1: Demographics and Characteristics of included studies
Study

Type

# pts Age
(yrs)
3449 18
years
or
older

Inclusion
Criteria
-legal age
of consent
-confirmed
DVT
-no
symptoms
of PE

Einstein1,
2010

RCT
Open label,
randomized,
even driven,
noninferiority
study

Agnelli2,
2007

RCT
parallelgroup phase
II trial

636

-age 18+
-no
symptoms
of PE
-not
received
VKA
-no more
than 36 hrs
of
treatment
with
LMWH

Romualdi3
2011

RCT
double blind,
placebo
controlled
superiority
study

1197 Mean
age
58
years

18
years
or
older

-Patients
with
confirmed
DVT

Exclusion Criteria

W/D Intervention

-Pts with heparin,
66
VKA treatment for
>48 hrs, treatment
with
thromboectomy,
vena cava filter, or
fibrinolytic agent,
liver disease,
active bleeding,
BP>180/110,
pregnancy,
CrCl<30ml/min,
bacterial
endocarditis, life
expectancy<3mos
-cerebral ischemia, 32
intracerebral
bleeding or GI
bleeding within
past 6 months,
surgery within past
4 weeks, active
PUD, known
bleeding disorder,
prolonged INR,
platelet count
<100X10^9/L,
body wt <45kg,
uncontrolled HTN,
heart failure,
CrCl<30ml/min,
pregnancy
-indication for
N/A
VKA, renal
insufficiency, liver
disease, bacterial
endocarditis,
active bleeding or
high risk of
bleeding,
uncontrolled HTN,
pregnancy

-regimen of
15 mg bid or
20mg QD
PO
rivaroxaban
-1.0 mg/kg
of body
weight bid
subQ
enoxaparin
+ VKA

-rivaroxaban
10, 20, or 30
mg BID or
40mg once
daily
-enoxaparin
1 mg/kg
BID
followed by
vitamin K
antagonist

-rivaroxaban
20mg once
daily

cessation and blood transfusions. The primary efficacy outcome was measured via checklist used
to identify signs and symptoms of recurrent DVT.
This review also looked at safety outcomes measured by percentage of treatment
emergent adverse events. The percentages reported were used to calculate Relative Risk Increase
(RRI) and Absolute Risk Increase (ARI). The ARI value is used to calculate the Numbers
Needed to Harm (NNH). The NNH tells the clinician how many patients can be treated with the
experimental treatment over the control treatment before one patient will be harmed.
Einstein’s 2010 study consisted of 3449 patients in whom 1731 were given rivaroxaban
while 1718 were given enoxaparin plus vitamin K antagonist. Patients were assigned to receive
oral rivaroxaban 15mg twice daily for the first three weeks, followed by 20mg once daily for the
anticipated 3, 6, or 12 months of treatment.1 Patients who received standard therapy received
subcutaneous enoxaparin 1.0 mg/kg, and either warfarin or acenocoumarol. Patients were
followed for the treatment duration and seen at fixed intervals that were identical for
experimental and comparison groups, at which time a checklist was used to elicit information on
symptoms and signs of recurrent VTE, bleeding, and adverse events.1 Adverse events leading to
discontinuation of study drug occurred in 4.9% of patients receiving rivaroxaban and 4.7% of
patients in the control group. Recurrent DVT occurred in 14 patients of the rivaroxaban group
compared to 28 patients receiving enoxaparin plus vitamin K antagonist. The primary efficacy
outcome occurred in 2.1% of patients in the rivaroxaban group and in 3% of patients in the
standard therapy group causing a hazard ratio of .68 and 95% CI of .44-1.04. The principal safety
outcome occurred in 139 patients in the rivaroxaban group and 138 patients receiving standard
therapy. The hazard ratio was .97 and 95% CI was .76 to 1.22. 196 patients in the rovaroxaban
discontinued treatment due to adverse events, consent withdrawn or lost to follow up. The NNH

value was 0 indicating no difference in major bleeding rates between the experimental and
control groups. The NNT value was -111 indicating for every 111th person treated with
rivaroxaban, DVT occurred in one less person. These results are summarized in tables 2 and 3.
Table 2: Adverse Event Data for Rivaroxaban
HARM
Einstein,
2010

CER
EER
(enoxaparin/VKA) (rivaroxaban)
.081
.081

RRI

ARI

NNH

CI

P-value

0

0

.76-1.22

.77

Table 3: Efficacy of Rivaroxaban in the Prevention of DVT
Prevention
Einstein,
2010

CER
EER
(enoxaparin/VKA) (rivaroxaban)
.03
.021

RRR

ARR

NNT

CI

P-value

-.30

-.009

-111

.441.04

<.001

In Roumaldi’s 2011 study, 1197 patients were enrolled in the study. 34.1% completed the
DVT study, 19.1% completed the PE study and 47.5% came from routine care.3 The average age
of patients was 58 years. The primary efficacy outcome occurred in 8 out of 602 patients in the
rivaroxaban group and 42 out of 594 patients in the placebo group for a hazard ratio of .18, 95%
CI of .09-.39and P-value<.001.3 Major bleeding occurred in 4 patients receiving rivaroxaban
with no episodes in patients receiving placebo. The net clinical benefit defined as the composite
of primary efficacy outcome and major bleeding, occurred in 12 patients receiving rivaroxaban
and in 42 patients receiving placebo, for a hazard ratio of .28 and 95% confidence interval of .15.53. 76 patients in the rivaroxaban group discontinued treatment due to adverse events,
withdrawn consent or lost to follow up. Non-major bleeding which consisted of mucosal
bleeding was increased from 1.2% in placebo group to 5.4% in those treated with rivaroxaban.
However patients continued treatment and overall benefits outweighed risks. The NNH value

was 143, which means for every 143 patients one more patient would have an episode of major
bleeding with rivaroxaban than with control after a period of time of 6 months. The NNT value
was -17 meaning for every 17th patient treated with rivaroxaban DVT occurred in one less
person with a 95% CI of .09-.39 and p-value<.001. These values are summarized in tables 4 and
5.
Table 4: Adverse Event Data for Rivaroxaban
HARM

CER (placebo)

Roumaldi,
2011

0

EER
(rivaroxaban)
.007

RRI

ARI

NNH

CI

P-value

.007

143

RRR

ARR

NNT

Ci

P-value

-.82

-.058

-17

.09-.39

<.001

.11

Table 5: Efficacy of Rivaroxaban in the Prevention of DV T
Prevention

CER (placebo)

Roumaldi,
2011

.071

EER
(rivaroxaban)
.013

In Agnelli’s 2007 study 636 patients were enrolled in the study. 613 patients were
randomized while 23 could not be randomized due to violation of protocol. An additional 9
patients did not receive treatment due to protocol violation or withdrawn consent leaving 602
patients who received study drug. Patients in the rivaroxaban were split up to receive either 10,
20, 30 milligrams twice daily or 40 milligrams once daily of rivaroxaban compared with
enoxaparin 1 mg/kg twice daily followed by vitamin K antagonist. Patients received treatment
for 12 weeks. The primary safety endpoint was major bleeding. Bleeding was considered major
if it was fatal, affected a critical organ, led to treatment cessation, or transfusion of two or more
units of blood.2 Major bleeding was observed in 1.7%, 1.7%, 3.3%, and 1.7% of patients
receiving rivaroxaban 10, 20, 30, milligrams twice daily or 40 milligrams once daily

respectively.2 No episodes of major bleeding occurred in the enoxaparin group. A total of 18
patients discontinued treatment due to protocol violation or lack of compliance. Table 6
summarizes incidence of major and non-major bleeding. The NNH value was 59 meaning for
every 59 patients one more patient would have an episode of major bleeding with rivaroxaban
than with control for a period of time of 12 weeks and a p-value of .39. These results are
summarized in table 7.
Table 6: Incidence of Adverse Events

Any bleeding
Major
bleeding
Bleeding
leading to
transfusion
Bleeding
warranting
treatment
cessation
Minor
bleeding
95% CI

10mg bid
(n=119)
6 (5%)
2 (1.7%)

Rivaroxaban
20mg BID
30mg BID
(n=117)
(n=121)
11 (9.4%)
13 (10.7%)
2 (1.7%)
4 (3.3%)

40mg QD
(n=121)
14 (11.6%)
2 (1.7%)

Enoxaparin/VKA
N=126
8 (6.3%)
0

2 (1.7%)

0

2 (1.7%)

1 (.8%)

0

1 (.8%)

2 (1.7%)

3 (2.5%)

1 (.8%)

0

4 (3.4%)

9 (7.7%)

11 (9.1%)

12 (9.9%)

8 (6.3%)

.2-5.9

.2-.6

.9-8.3

.2-5.8

.0-2.9

Table 7: Adverse Event Data for Rivaroxaban
HARM
Agnelli,
2007

CER
EER
(enoxaparin/VKA) (rivaroxaban)
0
.017

RRI

ARI

NNH

CI

P-value

.017

59

varied

.39

DISCUSSION
Rivaroxaban, a factor Xa inhibitor provides an advantage over other therapies due to its
oral route of administration, single drug approach, and does not require laboratory monitoring.

This provides advantages for physicians and patients, along with improving compliances.
Rivaroxaban is also a cost effective drug.
One of the most common uses of rivaroxaban includes DVT prophylaxis for patients
receiving hip or knee replacement surgery. Other indications of its use include pulmonary
embolism prophylaxis, atrial fibrillation and non-valvular cerebrovascular accident.
Contraindications to using rivaroxaban consist of active bleeding and hypersensitivity reaction to
the drug. There is insufficient evidence in relation to its use in pregnancy and is a category C
drug. The black box warning states that stopping rivaroxaban increases a patient’s risk of
thrombotic events such as stroke. Patients receiving neuraxial anesthesia or undergoing spinal
puncture and are using rivaroxaban can get epidural or spinal hematomas, which may result in
long term or everlasting paralysis. Aspirin, non-steroidal anti-inflammatory drugs, heparin, and
warfarin are amongst drugs that can cause increased risk of bleeding if taken with rivaroxaban.
The use of newer drugs may change the way anticoagulation clinics currently work. For
example the measurement of alternative blood tests such as D-dimer, ultrasound testing and
immediate availability in case of signs and symptoms or recurrence, bleeding, or other clinical
problems can be important.3
One limitation of Agnelli’s study is that study populations were younger, and few had
active cancer, which may have reduced the likelihood of thrombus extension or bleeding events.2
The Einstein study had an open design which allowed potential for a diagnostic suspicion bias.1
CONCLUSION
Rivaroxaban provides a solo drug approach to the short term and continued treatment of
venous thrombosis that may expand the benefits of anticoagulation. The studies presented in this

review support the safety and efficacy of using rivaroxaban in the treatment of DVT. The large
p-values for adverse events mean the prevention of bleeding may have occurred by chance or
coincidence. Rivaroxaban provides alternative treatment to other regimens such as enoxaparin
plus vitamin K antagonist. One of the major advantages of using rivaroxaban is that it does not
require laboratory monitoring and has decreased food and drug interactions. Another advantage
includes the drug’s oral route of administration.
Future studies should focus on finding the most effective and safe dosages for the use of
rivaroxaban. Dosages can be individualized to patients and also depend on other co-morbidities
present. Another area of interest is to assess the safety of rivaroxaban in distinct populations
including elderly, obese patients, patients with liver or renal impairment, and patients with
cancer. These are amongst some of the populations that were poorly represented in these studies.
Although DVT is less common in adolescents; the treatment of DVT with rivaroxaban in
adolescents with DVT should also be incorporated in future studies.
In conclusion, the factor Xa inhibitor rivaroxaban proves to be a safe and effective single
drug approach in the treatment of patients with symptomatic deep vein thrombosis.
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